Pre-market hot trades in US stocks: Clearmind Medicine pre-market down 7.03%; Corning pre-market down 3.40%

Pre-market Hot Trades in US Stocks

Clearmind Medicine is down 7.03% in pre-market trading. Based on recent key news:

1. On July 16, Clearmind Medicine announced that its intranasal MEAI formulation showed a higher nasal tissue retention rate compared to the standard solution in in vitro adhesion results. This data supports its intranasal project for alcohol use disorder, aiming to extend nasal cavity residence time to improve absorption and dose consistency. Following this news, market optimism about its technological prospects increased, but the stock price still fell.

2. On July 16, Clearmind Medicine, as a clinical-stage biotechnology company, focuses on the development of non-psychedelic neuroplasticity drugs, particularly for the treatment of alcohol use disorder, addiction, and weight management. Despite progress in technological research and development, the market remains cautious about its commercialization prospects, leading to stock price fluctuations.

3. On July 16, Clearmind Medicine released its latest research findings through GlobeNewswire, emphasizing the significant enhancement effects of its new formulation in the nasal drug delivery system. However, investor concerns about its future profitability may lead to a decline in stock price. The biotechnology industry has been volatile recently, and investors should exercise caution.

Corning is down 3.40% in pre-market trading. Based on recent news:

1. On July 17, JP Morgan placed Corning on its "negative catalyst watch" list ahead of its second-quarter earnings report, citing overvaluation. JP Morgan maintained a "neutral" rating with a target price of $200. Corning's stock price fell nearly 11% during the session.

2. On July 16, analyst Passage Research downgraded Corning's rating from "buy" to "sell," citing unsustainable valuation. Corning's stock price has increased nearly 100% year-to-date, but has recently pulled back.

3. On July 16, Corning plans to release its second-quarter earnings report on July 28, with market expectations of earnings per share at $0.75 and revenue at $4.63 billion. Despite positive expectations, valuation pressure has led to a decline in stock price. The market is cautious about high-valuation stocks, with noticeable capital outflows.

Top Gainers in Pre-market US Stocks

Polestar Automotive UK PLC is up 261.78% in pre-market trading. Based on recent news:

1. On July 17, the Chief Financial Officer of Volvo Cars stated that there are currently no plans to inject capital into Polestar. This news may have alleviated market concerns about Polestar's cash flow issues, driving the stock price significantly higher.

2. On July 17, the CEO of Volvo Cars confirmed holding a 20% stake in Polestar and has no intention of changing this ownership ratio. This news stabilized investor confidence in Polestar's equity structure, further boosting the stock price.

3. On July 16, Lucid Motors denied bankruptcy rumors, but market concerns about the long-term viability of electric vehicle companies led to fluctuations in Polestar's stock price Despite this, Polestar's stock price surged significantly in pre-market trading. The electric vehicle industry has been quite volatile recently, and investors should exercise caution.

Sadot rose 56.35% in pre-market trading. Based on recent key news:

1. On July 16, Sadot Group Inc. announced through the EDGAR system the termination of a $10 million equity credit agreement with Helena Global Investment Opportunities I. This move aims to resolve litigation and end financing obligations, with the agreement termination date set for July 15, involving an exit fee of $350,000. Following this announcement, the market's expectations for an improvement in the company's financial condition drove the stock price significantly higher. There is strong market expectation for the company's financial condition to improve.

Callan JMB rose 41.70% in pre-market trading. Based on recent key news:

1. On July 16, Callan JMB's management projected that new projects would generate approximately $414 million in revenue for the company over the next five years. This initiative is seen as a key role in creating a cutting-edge pharmaceutical manufacturing environment in the U.S., driving the stock price up.

2. On July 17, Benzinga Pro data showed that Callan JMB closed up 16.51% during regular trading hours, but its stock exhibited negative price trends across all time frames, indicating that the market still harbors doubts about its future performance.

3. On July 17, the overall market experienced significant volatility, with other companies like GrowHub and Netflix also showing substantial fluctuations, reflecting investors' concerns about market uncertainty. The market is notably volatile, and investors should exercise caution